View our list of available Coronavirus (COVID-19, SARS-CoV-2, 2019-nCOV) antibodies, recombinant proteins, ELISA Kits... Options Full Datasheet Printer Friendly Datasheet Prepare for Printing Full Datasheet Printer Friendly Datasheet Prepare for Printing Have Questions? Ask Us! Request A Quote Today! Add To Compare List HIV-1 Envelope conjugated to HIV-2 gp39 Recombinant Protein Catalog # MBS142617 Unit / Price 0.1 mg / $335 +1 FREE 8GB USB 0.5 mg / $830 +1 FREE 8GB USB 1 mg / $1,265 +1 FREE 8GB USB 5x1 mg / $5,355 +6 FREE 8GB USB Product Name Product Info Accession #s Product Desc Diseases/Tissues/Pathways Applications References Product Name HIV-1 Envelope conjugated to HIV-2 gp39, Recombinant Protein Full Product Name Recombinant HIV-1 Envelope conjugated to HIV-2 gp39 Product Synonym Names HIV-1, 2; HIV-1 envelope conjugated to HIV-2 gp39 Recombinant; HIV-1,2 Research Use Only For Research Use Only. Not for use in diagnostic procedures. TOP Host E Coli Specificity Immunoreactive with all sera of HIV-1, HIV type O & HIV-2 infected individuals. Purity/Purification Greater than 95.0% as determined by HPLC analysis and SDS-PAGE. Form/Format 100 mM Na-PO4, pH 6 & 0.05% SDS.Sterile filtered colorless clear solution. Other Notes Small volumes of HIV-1 Envelope conjugated to HIV-2 gp39 recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply. TOP Related Product Information for HIV-1 Envelope conjugated to HIV-2 gp39 recombinant protein Description: HIV-1,2 recombinant- E Coli derived recombinant 27 kDa protein contains the C- terminus of gp120 and most of gp41. The protein is conjugated to a 23 amino acids synthetic peptide derived from gp39 of HIV-2.Introduction: HIV-1 and HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears and vaginal fluids.Immunodeficiency develops more slowly with HIV-2.HIV-2 is less infectious in the early stages of the virus than with HIV-1.The infectiousness of HIV-2 increases as the virus progresses.Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection and often some degree of CD4-independence. Despite considerable sequence and phenotypic differences between HIV-1 and 2 envelopes, structurally they are quite similar. Both membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal and C-terminal regions of the ectodomain, which is common to many viral and cellular fusion proteins and which seems to drive fusion.HIV-1 gp41 helical regions can form more stable 6-helix bundles than HIV-2 gp41 helical regions however HIV-2 fusion occurs at a lower threshold temperature (25 degree C), does not require Ca2+ in the medium, is insensitive to treatment of target cells with cytochalasin B, and is not affected by target membrane glycosphingolipid composition. Product Categories/Family for HIV-1 Envelope conjugated to HIV-2 gp39 recombinant protein Viral Antigens; HUMAN IMMUNODEFICIENCY VIRUS; Viral Antigens; HIV Applications Tested/Suitable for HIV-1 Envelope conjugated to HIV-2 gp39 recombinant protein ELISA (EIA), Western Blot (WB) Application Notes for HIV-1 Envelope conjugated to HIV-2 gp39 recombinant protein HIV-1,2 antigen is suitable for ELISA and Western blots, excellent antigen for early detection of HIV seroconvertors with minimal specificity problems. TOP Precautions All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines. Disclaimer While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information. TOP